welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Biomarker for Duchenne Muscular Dystrophy (BioDuchenne)
study id #: NCT02994030
condition: Increased Lordosis/Scoliosis, Hyporeflexia, Duchenne Muscular Dystrophy, Red-Green Color Blindness, Lordosis, Scoliosis, Muscular Atrophy, Muscular Weakness
International, multicenter, observational, longitudinal study to identify biomarker/s for Duchenne Muscular Dystropy (DMD) and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s.
mechanism of action: No pharmaceutical intervention
last updated: August 14, 2020
start date: August 20, 2018
estimated completion: December 2023
phase of development: N/A
size / enrollment: 1000
Duchenne Muscular Dystrophy (DMD) is a devastating inherited neuromuscular disorder that affects 1 in 3300 live male births (females can be mildly affected carriers). DMD causes progressive weakness and loss of muscle mass, with symptoms usually appearing in early childhood. DMD arises from mutations in the DMD gene that codes for dystrophin.
The DMD gene is located on the short arm of chromosome X (locus Xp21) and codes for dystrophin, containing 3685 amino acid residues. 60-65% of DMD mutations are large dele-tions, 10-30% are nonsense and frame-shift mutations, 5-15% are duplications, and 2% are intronic or 5`- and 3`-UTR alterations.Dystrophin aggregates as a homotetramer in the skeletal muscles or associates with actin and Dystrophin-Associated Glycoproteins (DAGs), forming a stable complex that interacts with laminin in the extracellular matrix. Dystrophin is considered a key structural element in the muscle fiber, whose primary function is to stabilize plasma mem-brane, while the DAGs maintain the sarcolemmal stability by mediating the complex interactions of the muscle membrane and extracellular environment. The low levels of dystrophin lead to cellular instability and progressive leakage of intracellular components, explaining the characteristically high levels of creatine phosphokinase (CPK) in the blood of DMD patients.
Biomarkers serve as measurable indicators of normal biological or pathological processes. They are typically directly linked to genetic variants in specific genes and can predict, diagnose, monitor, and assess the severity of a disease. It is the goal of this study to identify, validate, and monitor biochemical markers from DMD affected participants.
- Identification of DMD biomarker/s [ Time Frame: 36 weeks ]
All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.
- Exploring the clinical robustness, specificity, and long-term variability of DMD biomarker/s [ Time Frame: 36 months ]
Samples will be analyzed for the identified biomarker candidates via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.
• Eligible Sexes: all
• The participant is aged between 2 months and 50 years
• The diagnosis of DMD is genetically confirmed by Centogene
• Informed consent is not obtained from the parent/ legal guardian.
• The participant is younger than 2 months or older than 50 years
• The diagnosis of DMD is not genetically confirmed by Centogene
Biomechanical and Morphological Changes in Dystrophic MuscleThe loss of ability to walk in many chil...
Design of a phase 3 trial to evaluate the long-term efficacy and safety of ataluren in patients with nonsense mutati...Ataluren is conditionally approved by th...
Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy (PolarisDMD)The PolarisDMD study is a Phase 3, globa...
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular DystrophyThe primary objective of this study is t...
Research of Biomarkers in Duchenne Muscular Dystrophy PatientsThe purpose of this study is to identify...
Clay Matthews Supports Duchenne Muscular Dystrophy and First Approved Treatmenthttps://www.youtube.com/watch?v=WPu5pGEF...
A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular DystrophyThe purpose of this study is to determin...
Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access programSince the 1970s, the FDA has helped to f...
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy ProgramSarepta Therapeutics, Inc., a commercial...
Antisense Therapeutics to commence muscular dystrophy trialsAntisense Therapeutics is planning to un...